COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

New Funding Opportunity: Tissue Purchase Order Acquisitions

The National Cancer Institute (NCI) is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality, well annotated biospecimens suitable for use in genomic and proteomic studies.  The NCI’s overarching goal with such programs is to improve the ability to diagnose, treat, and prevent cancer.

A goal of the next phase of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to leverage the investments in cancer genomics and achievements in cancer proteomics and apply it to additional cancer types where questions remain unanswered on the complexity between the proteome and the genome in cancer.  A component of this goal is the acquisition of high‐quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types.